ClinicalTrials.gg
RecruitingNCT04163081INITIATEUpdated Nov 4, 2026

The INITIATE Study: Initiating Nicotine Dependence Treatment for Smokers Admitted to Emergency Departments

An interventional study of Quit Card Intervention (QCI) in Nicotine Dependence, Cigarettes and Nicotine Withdrawal, sponsored by Ottawa Heart Institute Research Corporation. Recruiting at 4 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Ottawa Heart Institute Research Corporation · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 7 months later.
Updated Nov 4, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,208
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Tobacco Use Disorder with a site in Canada — 10 open to participants now, 10 under way, 1 of them phase 3. Tobacco Use Disorder · Canada.

Planned enrollment
3rd of 41
1,208 · median 43
Started
2022
with 1 other
No phase
19 of 43
4 open now
Registered
34th of 43
by date
Lead sponsor
2 of 43
Ottawa Heart Institute Research Corporation

Among the 43 studies in Tobacco Use Disorder with a site in Canada, this one is the 3rd largest by planned enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2022, is one of 19 with no phase, and was the 34th registered.

Tobacco Use Disorder

1,028 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.

Browse Tobacco Use Disorder studies →

Open to participants now

10 of the 43 studies in Tobacco Use Disorder with a site in Canada are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 95 Tobacco Use Disorder studies recruiting now, 42 (44%) set no upper age limit and 50 (53%) stop at 75 or younger; 6 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Tobacco Use Disorder with a site in Canada, or all of them as a file.
02

Study summary

The INITIATE Study is a randomized controlled trial that is testing an intervention designed to increase long-term abstinence among tobacco smokers seen in emergency departments (ED) and other high-volume hospital and community ambulatory care settings. The intervention includes a behavioural incentive and tailored follow-up support on long-term smoking abstinence, health, healthcare utilization, and cost. Tobacco-related illnesses cost the healthcare system millions each year. Quitting smoking improves smoking-related outcomes, like the onset or management of heart disease, stroke, lung diseases, and several cancers. There are approximately 16 million visits to Canadian EDs each year; an estimated 3-4 million of these involve smokers. Effective quit smoking interventions exist, but are underutilized. Few hospital EDs, community healthcare centers, and other inpatient and outpatient clinics in Canada offer tobacco-use interventions. In order for clinicians to offer quit smoking support, interventions need to be simple given the realities of these high-volume environments. Considering that stopping smoking improves health outcomes, that tobacco-use is an important cause of preventable ED use, and the volume of smokers, Canadian EDs and other high-volume hospital and community ambulatory care settings are a missed opportunity in the initiation of quit smoking support. Our intervention has been designed to optimize uptake and smoking abstinence by including the most effective evidence-based behavioural and drug-related approaches, removing specific barriers and challenges that smokers face when trying to quit (e.g., affordability, low confidence and motivation), while packaging the intervention in a quick-to-initiate manner, making it ideal for fast-paced, complex environments.

03

Conditions studied

  • Nicotine Dependence, Cigarettes
  • Nicotine Withdrawal

Keywords

  • Nicotine Replacement Therapy
  • Emergency Department
  • Nicotine Dependence
  • Tobacco Abstinence
  • Tobacco Treatment
  • Cigarette
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Current daily smoker (smokes ≥ 5 cigarettes per day);
  • ≥ 18 years of age (the age of majority in Ontario);
  • For ED sites only, assigned a CTAS level of 2-5 (emergent to non-urgent);
  • Able to read and understand English or French;
  • Resides in Ontario and eligible for Ontario Health Insurance Plan (to permit linkage with administrative data housed at the Institute for Clinical Evaluative Sciences [ICES]);
  • Available and willing to participate in follow-up assessments over the next 12 months;
  • Has access to a telephone or computer;
  • Able to provide

Exclusion criteria

Exclusion Criteria:

  • Currently participating in this or another smoking cessation study;
  • For ED sites only, assigned a CTAS level of 1 (resuscitation - the most seriously ill patients with highest likelihood of hospital admission) or in psychiatric emergency unit;
  • Pregnant, planning to become pregnant over the next year, or breastfeeding;
  • Has morbid illness which will prevent completion of 26-week follow-up (e.g., receiving palliative care);
  • In the opinion of the attending physician, manifests acute physical and/or psychiatric illness or has cognitive impairment that would preclude participation in/benefit from the intervention.
  • Scheduled for a known elected surgery, procedure, or future hospitalization during the study period.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
1,208 participants (estimated)

Study arms

  • Experimental
    Quit Card Intervention (QCI)

    Study intervention group.

    Behavioral: Quit Card Intervention (QCI)

  • No intervention
    Usual Care (UC)

    Study control group.

Interventions

  • BehavioralQuit Card Intervention (QCI)

    The intervention is comprised of a behavioural incentive in the form of a gift card as well as tailored smoking cessation counseling. Eligible consenting smokers randomized to the QCI group will receive: a "Quit Card" (a gift card worth $300 that can be used to buy nicotine replacement therapies at any pharmacy); self-help information; and, enrollment in six months of telephone follow-up support tailored by treatment goal with a Nicotine Addiction Treatment Specialist.

06

What researchers measure

Primary outcomes

  1. Smoking Abstinence

    Smoking abstinence at 26 weeks, biochemically verified using an expired air carbon monoxide (CO) test

    Time frame: 26 weeks (6 months) after study enrollment

Secondary outcomes

  1. Prolonged Abstinence

    Prolonged (since last time point) smoking abstinence, at 4, 26, and 52 weeks

    Time frame: 4, 26, and 52 weeks after study enrollment

  2. Point Prevalence Abstinence

    Point prevalence smoking abstinence, at 4, and 52 weeks

    Time frame: 4, and 52 weeks after study enrollment

  3. Smoking Reduction

    Smoking reduction (i.e., change in number of daily cigarettes), at 4, 26, and 52 weeks

    Time frame: 4, 26, and 52 weeks after study enrollment

  4. Number of Quit Attempts

    Number of quit attempts since study entry, at 4, 26, and 52 weeks

    Time frame: 4, 26, and 52 weeks after study enrollment

  5. Cessation Medication and/or E-cigarette Use

    Use of smoking cessation medication and/or e-cigarette, at 4, 26, and 52 weeks

    Time frame: 4, 26, and 52 weeks after study enrollment

  6. Use of Behavioural Supports

    Use of behavioural supports (e.g., counseling, quit lines), at 4, 26, and 52 weeks

    Time frame: 4, 26, and 52 weeks after study enrollment

  7. Health-Related Quality of Life

    Health-related quality of life (HR-QoL), at 52 weeks. This will be measured using the Hospital Anxiety and Depression Scale (HADS), designed to identify and measure the levels of anxiety and depression among individuals in non-psychiatric hospital settings, and the Health Questionnaire Assessment (EQ-5D-5L), using five graded severity levels to summarize perceived health across five foundational dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

    Time frame: 52 weeks after study enrollment

  8. Health Services Outcomes - ED visits

    Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) visits to ED at 4, 26, and 52 weeks

    Time frame: 4, 26, and 52 weeks after study enrollment

  9. Health Services Outcomes - Hospital Admissions

    Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) admissions to hospital at 4, 26, and 52 weeks

    Time frame: 4, 26, and 52 weeks after study enrollment

  10. Health Services Outcomes - Deaths

    Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) deaths at 4, 26, and 52 weeks

    Time frame: 4, 26, and 52 weeks after study enrollment

  11. Cost-Effectiveness Ratios

    Cost-effectiveness ratios related to health services at 52 weeks

    Time frame: 52 weeks after study enrollment

07

Study locations

4 of 4 sites recruiting
  • Civic Hospital
    Ottawa, Ontario, Canada
    Recruiting
    • Dr. Venkatesh Thiruganasambandamoorthy · Contactvthirug@toh.ca · 6137985555,17023
  • General Hospital
    Ottawa, Ontario, Canada
    Recruiting
    • Dr. Venkatesh Thiruganasambandamoorthy · Contactvthirug@toh.ca · 6137985555,17023
  • Riverside Hospital
    Ottawa, Ontario, Canada
    Recruiting
    • Dr. Venkatesh Thiruganasambandamoorthy · Contactvthirug@toh.ca · 6137985555,17023
  • University of Ottawa Heart Institute
    Ottawa, Ontario, Canada
    Recruiting
08

References and documents

Publications

  • Mullen KA, Garg A, Gagnon F, Wells G, Kapur A, Hawken S, Pipe AL, Walker K, Thiruganasambandamoorthy V, Klepaczek M, Reid RD. The INITIATE trial protocol: a randomized controlled trial testing the effectiveness of a "quit card" intervention on long-term abstinence among tobacco smokers presenting to the emergency department. Trials. 2021 Oct 23;22(1):733. doi: 10.1186/s13063-021-05693-9. PubMed 34688291 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Sep 2027, 65 months after the start.

Of 257 non-industry interventional studies with no phase under Tobacco Use Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 51. This study's planned 65 months is above that.

Counting every sponsor, half of 267 studies reached it within 32 months; a quarter within 16 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Sep 2026 → Sep 2027 and completion Mar 2027 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2019
First posted
Nov 14, 2019
StartActual
Apr 19, 2022
Primary completionEst.
Sep 2027was Sep 2026
CompletionEst.
Sep 2027was Mar 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Sep 2027
Nov 4, 2026
Study completion
Mar 2027→Sep 2027
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Primary completion Sep 2026→Sep 2027
    Study completion Mar 2027→Sep 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04163081
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Sponsor
First posted
Nov 14, 2019
Start date
Apr 19, 2022
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Chantelle Masterson, BPhil
Contact
cmasterson@ottawaheart.ca
613-696-7000 ext. 19157
Evyanne Wooding, R.Kin
Contact
ewooding@ottawaheart.ca
613-696-7000 ext. 17596
Kerri-Anne Mullen, PhD
principal investigator · Ottawa Heart Institute Research Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion